Agilent Technologies Aktie
WKN: 929138 / ISIN: US00846U1016
14.11.2022 14:00:00
|
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0
Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that allow AssayMAP Bravo-based automated sample preparation in workflows across the biopharma drug development process.
The requirement for labs to use instruments that comply with regulatory guidelines such as 21 CFR Part 11 or have the option of turning on compliance-enabling software features is moving to earlier stages of the drug development process. The AssayMAP Workbench 4.0 addresses these requirements and facilitates the seamless transfer of assays along the entire drug development process, including moving from non-compliant to compliant laboratories.
AssayMAP Workbench 4.0 simplifies the documentation required in regulated laboratories and desired in non-regulated labs by providing the option to generate reports that capture sample prep workflow data. The new AssayMAP software enables novice users to use the system with minimal training by providing a walk-up operation option.
"The addition of compliance enabling features, walk-up capabilities, and report generation provide our customers added value across the entire biopharma drug development process,” said Lars Kristiansen, general manager of Agilent’s Automation Solutions business. "These enhancements align with our focus to provide new solutions to our biopharma partners that enable them to bring biotherapeutics to market faster and more cost-effectively.”
AssayMAP Workbench 4.0 also expands software support for the recently released AssayMAP large-capacity cartridges. These cartridges enhance the ability of biopharma labs to analyze biotherapeutic critical quality attributes and enable more complete automation of sample prep workflows.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005435/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Agilent Technologies Inc.mehr Nachrichten
16.09.25 |
S&P 500-Papier Agilent Technologies-Aktie: So viel hätte eine Investition in Agilent Technologies von vor 5 Jahren abgeworfen (finanzen.at) | |
09.09.25 |
S&P 500-Titel Agilent Technologies-Aktie: So viel Verlust hätte ein Investment in Agilent Technologies von vor 3 Jahren eingebracht (finanzen.at) | |
02.09.25 |
S&P 500-Wert Agilent Technologies-Aktie: So viel Verlust hätte ein Investment in Agilent Technologies von vor einem Jahr bedeutet (finanzen.at) | |
28.08.25 |
Handel in New York: Zum Ende des Donnerstagshandels Pluszeichen im S&P 500 (finanzen.at) | |
28.08.25 |
Starker Wochentag in New York: S&P 500 mit Zuschlägen (finanzen.at) | |
28.08.25 |
Gute Stimmung in New York: So steht der S&P 500 am Mittag (finanzen.at) | |
28.08.25 |
Donnerstagshandel in New York: S&P 500 verliert zum Start (finanzen.at) | |
26.08.25 |
S&P 500-Titel Agilent Technologies-Aktie: So viel Gewinn hätte ein Agilent Technologies-Investment von vor 10 Jahren eingefahren (finanzen.at) |
Analysen zu Agilent Technologies Inc.mehr Analysen
Aktien in diesem Artikel
Agilent Technologies Inc. | 108,20 | 0,73% |
|